OSCR Quantitative Stock Analysis

Validea's guru fundamental report rates Oscar Health Inc. (OSCR) at 60% using Kenneth Fisher's Price/Sales Investor model, which is below the 80% threshold typically indicating 'some interest' for this value strategy. While OSCR passes on its price-to-sales ratio and free cash per share, it notably fails criteria for long-term EPS growth and three-year average net profit margin, suggesting fundamental weaknesses that temper its appeal despite favorable valuation metrics within this specific framework.

Analysis

According to a Validea fundamental report, Oscar Health Inc. (OSCR) scores 60% based on the Kenneth Fisher Price/Sales Investor model, a rating that falls short of the 80% threshold typically indicating investment interest for this strategy. The analysis presents a mixed profile for the mid-cap growth stock. On one hand, OSCR demonstrates strength in valuation-focused metrics, passing tests for its Price/Sales Ratio and Free Cash Per Share. However, these positive attributes are counterbalanced by significant fundamental weaknesses. The company fails on crucial criteria for long-term EPS growth and its three-year average net profit margin, suggesting that despite an appealing valuation relative to sales, its underlying profitability and growth profile are currently unsatisfactory according to this specific value-oriented framework.

Key Decisions for Investors

• Investors should recognize the divergence between Oscar Health's attractive valuation metrics, such as its Price/Sales ratio, and its fundamental deficiencies, specifically the lack of long-term EPS growth and poor historical profit margins.
• Given the 60% score is materially below the 80% interest threshold for the Kenneth Fisher model, investors following this specific value strategy should exercise caution, as the stock does not meet the full criteria for a compelling investment.
• Prospective or current shareholders should closely monitor future earnings reports for a clear turnaround in net profit margins and evidence of a sustainable path to EPS growth before weighting the favorable valuation metrics too heavily.